NEW YORK, Nov. 7 - Lion Bioscience and Paradigm Genetics said Wednesday they have expanded a five-year strategic alliance to jointly develop a metabolic profiling database.
Under the terms of the new arrangement, the companies, which first penned their deal to build MetaTrace in 2000, will add biochemical data.
When completed MetaTrace will include profiling data mostly from human cells, fluids, and tissues.
The MetaTrace database and the visualization software it comes will are designed to give researchers useful information for target identification and validation.
"By analyzing the biochemical profiles in healthy and diseased tissues, as well as in human cell lines and fluids with our metabolomics technologies, and integrating it with Lion's leading integrated life science informatics software, researchers can identify disease related pathways and potential drug candidates early in the process," John Ryals, CEO of Paradigm Genetics, said in a statement.
According to the deal, Paradigm will determine biochemical profiles in both healthy and diseased tissues. Lion's software tools can then be used to identify genes related to the profile and pathways can be elucidated, the companies said.
Lion of Heidelberg, Germany, and Paradigm of Research Triangle Park, NC, did not disclose the financial terms of the expanded deal.
On Tuesday Paradigm said it had forged a partnership with Thermo Electron to jointly design new technologies for use in metabolomics.